Condition: Sarcopenia in Elderly · Sponsor: Pluto Inc.
This is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of PLH-2301 in subjects with sarcopenia. Eligible subjects aged 65 years and older will be randomized to receive placebo or one of three dose levels of PLH-2301 once daily for 12 weeks. The primary objective is to assess the effect of PLH-2301 on physical function compared with placebo.
This description comes directly from the study's public registry record.
CRO PM · +82-70-4335-4755 · mskim1@symyoo.com
Always discuss trial participation with your own doctor first.
| Seoul National University Bundang Hospital | Seongnam-si, Gyeonggi-do, South Korea | Recruiting |
| The Catholic University of Korea, St. Vincent's Hospital | Suwon, Gyeonggi-do, South Korea | Recruiting |
| Korea University Anam Hospital | Seoul, Seoul, South Korea | Recruiting |
| Seoul St. Mary's Hospital | Seoul, Seoul, South Korea | Recruiting |
| Korea University Guro Hospital | Seoul, Seoul, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07390552